BR112021026170A2 - Composição farmacêutica para tratamento de tumor?? - Google Patents

Composição farmacêutica para tratamento de tumor??

Info

Publication number
BR112021026170A2
BR112021026170A2 BR112021026170A BR112021026170A BR112021026170A2 BR 112021026170 A2 BR112021026170 A2 BR 112021026170A2 BR 112021026170 A BR112021026170 A BR 112021026170A BR 112021026170 A BR112021026170 A BR 112021026170A BR 112021026170 A2 BR112021026170 A2 BR 112021026170A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
tumor treatment
pharmaceutically acceptable
acceptable salt
antitumor effect
Prior art date
Application number
BR112021026170A
Other languages
English (en)
Portuguese (pt)
Inventor
Takuya Suzuki
Taro Semba
Yasuhiro Funahashi
Original Assignee
Eisai R&D Man Co Ltd
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Ono Pharmaceutical Co filed Critical Eisai R&D Man Co Ltd
Publication of BR112021026170A2 publication Critical patent/BR112021026170A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021026170A 2019-07-26 2020-07-27 Composição farmacêutica para tratamento de tumor?? BR112021026170A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019138041 2019-07-26
US16/835,719 US11083705B2 (en) 2019-07-26 2020-03-31 Pharmaceutical composition for treating tumor
PCT/JP2020/028663 WO2021020336A1 (ja) 2019-07-26 2020-07-27 腫瘍治療用医薬組成物

Publications (1)

Publication Number Publication Date
BR112021026170A2 true BR112021026170A2 (pt) 2022-02-15

Family

ID=74187564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026170A BR112021026170A2 (pt) 2019-07-26 2020-07-27 Composição farmacêutica para tratamento de tumor??

Country Status (14)

Country Link
US (2) US11083705B2 (https=)
EP (1) EP3970745A4 (https=)
JP (1) JP7649742B2 (https=)
KR (1) KR20220041044A (https=)
CN (1) CN113993545A (https=)
BR (1) BR112021026170A2 (https=)
CA (1) CA3143486A1 (https=)
IL (1) IL289213A (https=)
MA (1) MA55982A (https=)
MX (1) MX2021016093A (https=)
PH (1) PH12021553177A1 (https=)
TW (4) TWI904982B (https=)
WO (1) WO2021020336A1 (https=)
ZA (1) ZA202110686B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN116407492B (zh) * 2021-12-29 2024-11-05 北京新领先医药科技发展有限公司 一种甲磺酸艾日布林注射液组合物及制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5551683B2 (https=) 1972-10-23 1980-12-25
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
AU2002340670A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
BR0317882A (pt) 2002-12-31 2005-12-13 Bharat Serums & Vaccines Ltd Processo para fabricação de lipossomas de longa circulação não tratados com peg; lipossoma; composição de doxorrubicina lipossomal de longa duração não tratada com peg; e método
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP1618897A4 (en) 2003-04-04 2010-09-29 Eisai R&D Man Co Ltd LIPID MEMBRANE STRUCTURE COMPRISING AN ANTI-MT-MMP MONOCLONAL ANTIBODY
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
CA2553573A1 (en) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. Method for stabilizing macrolide compound
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
EP1750673B1 (en) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
WO2006037230A1 (en) 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090196913A1 (en) 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
US20090196917A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102369008B (zh) * 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
JP5388735B2 (ja) 2009-07-21 2014-01-15 浜松ホトニクス株式会社 マイクロチャンネルプレート
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHOD FOR THEIR USE
AU2012284147A1 (en) 2011-07-19 2014-02-27 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
ES2822665T3 (es) 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
BR112015029386B1 (pt) 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
WO2015042279A1 (en) 2013-09-18 2015-03-26 Stc. Unm Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US20170020817A1 (en) 2013-12-19 2017-01-26 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtuble inhibitors with reduced ostwald repening for oral administration
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CA2940983A1 (en) 2014-03-03 2015-09-11 Eisai R&D Management Co., Ltd. Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
KR20240144452A (ko) 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物
AU2016226157B2 (en) * 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2018071792A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control

Also Published As

Publication number Publication date
EP3970745A1 (en) 2022-03-23
AU2020323402A1 (en) 2022-01-27
TW202515533A (zh) 2025-04-16
JPWO2021020336A1 (https=) 2021-02-04
WO2021020336A1 (ja) 2021-02-04
KR20220041044A (ko) 2022-03-31
TW202515532A (zh) 2025-04-16
US20210023047A1 (en) 2021-01-28
TWI904981B (zh) 2025-11-11
TW202515534A (zh) 2025-04-16
ZA202110686B (en) 2022-09-28
IL289213A (en) 2022-02-01
CN113993545A (zh) 2022-01-28
CA3143486A1 (en) 2021-02-04
PH12021553177A1 (en) 2022-11-07
TWI865566B (zh) 2024-12-11
TW202118486A (zh) 2021-05-16
MX2021016093A (es) 2022-02-03
TWI904982B (zh) 2025-11-11
NZ783713A (en) 2025-06-27
MA55982A (fr) 2022-03-23
EP3970745A4 (en) 2023-07-19
US11083705B2 (en) 2021-08-10
JP7649742B2 (ja) 2025-03-21
US20210177802A1 (en) 2021-06-17
TWI904983B (zh) 2025-11-11

Similar Documents

Publication Publication Date Title
BR112021026170A2 (pt) Composição farmacêutica para tratamento de tumor??
CO2026004076A2 (es) Compuestos macrocíclicos, método de preparación de estos y uso de estos
BR112022008534A2 (pt) Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112022008535A2 (pt) Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
CO2021008895A2 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2019013878A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112022003434A2 (pt) Composição de liberação retardada de niclosamida e uso antiviral da mesma
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica